title: Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
abstract: OBJECTIVE
  Most patients with localized high-grade non-Hodgkin's lymphoma (NHL) can be cured with or without adjuvant radiotherapy. However few data are available on the long-term outcome of these patients. Here we report the results of a prospective study, started in 1984, which was conducted to evaluate the long-term outcome of patients with localized high-grade NHL.
  
  
  METHODS
  In this multicenter, prospective study by the GOELAMS group, 253 patients with localized high-grade NHL were treated with 3 cycles of vindesine, cyclophosphamide, adriamycin and prednisone (VCAP, a high-dose CHOP regimen) followed by involved field radiotherapy (40 Gy).
  
  
  RESULTS
  After completion of chemotherapy, 213 patients (84%) entered complete remission (CR) and 30 (12%) obtained a partial remission. Treatment failed in 6 patients (2.5%) and there were 4 toxic deaths (1.5%). Following radiotherapy, 239 (94%) of all patients were in CR. With a median follow-up of 88 months, overall survival and disease-free survival rates were 84% and 85% respectively at five years, and 78% and 82% respectively at ten years. The response to chemotherapy was decisive to survival. We observed 43 relapses (17%) at a median time of 20 months after CR, and 9 patients relapsed after five years. Eleven patients (3%) developed another malignancy in the follow-up period.
  
  
  CONCLUSIONS
  High-dose CHOP followed by locoregional radiotherapy is a feasible treatment for localized high-grade NHL. It has very few complications, a good CR rate and the OS is 78% at 10 years.
authors.forename: Marc
authors.initials: M
authors.lastname: Bernard
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.forename: Petronella
authors.initials: P
authors.lastname: Rachieru
authors.forename: Annick
authors.initials: A
authors.lastname: LeMevel
authors.forename: Bernard
authors.initials: B
authors.lastname: Branger
authors.forename: Catherine
authors.initials: C
authors.lastname: Le Maignan
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
authors.forename: Christiane
authors.initials: C
authors.lastname: Ghandour
authors.forename: Vincent
authors.initials: V
authors.lastname: Delwail
authors.forename: Noel
authors.initials: N
authors.lastname: Milpied
authors.forename: Philippe
authors.initials: P
authors.lastname: Cassasus
authors.forename: Philippe Solal
authors.initials: PS
authors.lastname: Celigny
authors.forename: Dominique
authors.initials: D
authors.lastname: Guyotat
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.forename: Bernard
authors.initials: B
authors.lastname: Desablens
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone